title: Antioxidant status, erythrocyte membrane lipid peroxidation and osmotic fragility in malignant lymphoma patients.
abstract: We studied erythrocyte and leukocyte superoxide dismutase and catalase activities, erythrocyte malondialdehyde (MDA) and osmotic fragility and plasma L-ascorbic acid and L-dehydroascorbic acid levels in adult patients with acute lymphoblastic leukemia (ALL), Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) before and after treatment. SOD activity was elevated in leukocytes of ALL and HD patients before treatment, and borderlike-significantly elevated in leukocytes of the same patients after treatment in comparison to the control subjects. SOD activity was not changed in NHL patients before or after chemotherapy. Erythrocyte superoxide dismutase and catalase activities were elevated in the three groups of lymphomas before and after treatment. MDA level and osmotic fragility of red blood cells of patients with lymphomas were increased before and after treatment in comparison to the control group. Plasma L-ascorbic acid concentrations were decreased, whereas L-dehydroascorbic acid concentrations were increased in ALL, HD and NHL patients before and after treatment. There were also significant differences in the activities of the antioxidant enzymes, concentrations of antioxidants, MDA and osmotic fragility in the most of the malignant lymphoma patients. The present data suggest that hematological complications and autoimmune hemolytic anemia might be attributed to the oxidative stress produced by malignant lymphomas.
authors.affiliation: Biochemistry Department, Faculty of Science, Mansoura University, Egypt. sinfac@mum.mans.eun.eg
authors.forename: M A
authors.initials: MA
authors.lastname: Abou-Seif
authors.forename: A
authors.initials: A
authors.lastname: Rabia
authors.forename: M
authors.initials: M
authors.lastname: Nasr
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000378:metabolism*; D001205:Ascorbic Acid / Q000097:blood; D016022:Case-Control Studies; D002374:Catalase / Q000097:blood / Q000378:metabolism; D003683:Dehydroascorbic Acid / Q000378:metabolism; D004910:Erythrocyte Membrane / Q000201:enzymology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007962:Leukocytes / Q000201:enzymology / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D008223:Lymphoma / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009996:Osmotic Fragility / Q000187:drug effects; D018384:Oxidative Stress; D013482:Superoxide Dismutase / Q000097:blood / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D008315:Malondialdehyde; D002374:Catalase; D013482:Superoxide Dismutase; D001205:Ascorbic Acid; D003683:Dehydroascorbic Acid